Eye movement alterations in presymptomatic C9orf72 expansion gene carriers

Anna Behler · Antje Knehr · Julia Finsel · Martin S. Kunz · Christina Lang · Kathrin Müller · Hans-Peter Müller · Elmar H. Pinkhardt · Albert C. Ludolph · Dorothée Lulé · Jan Kassubek

Received: 21 January 2021 / Revised: 4 March 2021 / Accepted: 5 March 2021 / Published online: 11 March 2021
© The Author(s) 2021

Abstract
Objective The clinical manifestation of amyotrophic lateral sclerosis (ALS) is characterized by motor neuron degeneration, whereas frontotemporal dementia (FTD) patients show alterations of behavior and cognition. Both share repeat expansions in C9orf72 as the most prevalent genetic cause. Before disease-defining symptoms onset, structural and functional changes at cortical level may emerge in C9orf72 carriers. Here, we characterized oculomotor parameters and their association to neuropsychological domains in apparently asymptomatic individuals with mutations in ALS/FTD genes.

Patients and methods Forty-eight carriers of ALS genes, without any clinical symptoms underwent video-oculographic examination, including 22 subjects with C9orf72 mutation, 17 with SOD1, and 9 with other ALS associated gene mutations (n = 3 KIF5A; n = 3 FUS/FUS+TBK1; n = 1 NEK1; n = 1 SETX; n = 1 TDP43). A total of 17 subjects underwent a follow-up measurement. Data were compared to 54 age- and gender-matched healthy controls. Additionally, mutation carriers performed a neuropsychological assessment.

Results In comparison to controls, the presymptomatic subjects performed significantly worse in executive oculomotor tasks such as the ability to perform correct anti-saccades. A gene mutation subgroup analysis showed that dysfunctions in C9orf72 carriers were much more pronounced than in SOD1 carriers. The anti-saccade error rate of ALS mutation carriers was associated with cognitive deficits: this correlation was increased in subjects with C9orf72 mutation, whereas SOD1 carriers showed no associations.

Conclusion In C9orf72 carriers, executive eye movement dysfunctions, especially the increased anti-saccade error rate, were associated with cognitive impairment and unrelated to time. These oculomotor impairments are in support of developmental deficits in these mutations, especially in prefrontal areas.

Keywords Amyotrophic lateral sclerosis · C9orf72 · Saccades · Cognition · Presymptomatic gene carriers

Introduction
The underlying pathological process in neurodegenerative conditions likely begins some time before the emergence of clinical symptoms. Signs may be decades long in many neurodegenerative disorders (like Parkinson’s and Alzheimer’s disease), but there is still limited knowledge about the duration of the presymptomatic phase of amyotrophic lateral sclerosis (ALS) [1]. From an academic perspective, studies in the presymptomatic phase offer invaluable learning opportunities to study propagation patterns, characterize early genotype-associated signatures, and evaluate neurodevelopmental or environmental factors [2]. While ALS is primarily characterized by motor neuron degeneration, cognitive deficits are quite common [3–5], including changes in executive functions together with verbal fluency, language, social cognition, and memory. These deficits could be associated with white matter changes in frontal areas in ALS patients [5, 6]. Recently, alterations in the executive function of verbal fluency associated with a loss of structural integrity...
were observed in presymptomatic C9orf72 carriers [7], i.e., in subjects with a hexanucleotide GGGGCC-repeat expansion in C9orf72 which is the most prevalent genetic cause of ALS and frontotemporal dementia (FTD) in Caucasian populations [8]. Given that the C9orf72 protein is believed to play a key role in the development of the central nervous system [9], cerebro-structural and functional (e.g. neuropsychological) dysfunctions in a preclinical state support the assumption of a developmental tardiness as a general trait in C9orf72 carriers [7]. Presymptomatic SOD1 gene carriers also showed changes in advance of symptom onset such as a reduced number of motor units, increased cortical excitability, and differences in cervical cord tissue metabolites [10].

Although a relative preservation of eye movements is recognized as a feature of ALS, eye-tracking offers an objective means to assess extramotor cerebral involvement in ALS [11]. The oculomotor parameters being most prominently affected in ALS are assigned to frontal lobe impairment [12, 13]. Similar alterations with joint occurrence of increased error rates of anti-saccades and delayed saccades have been reported for patients with FTD [14]. For oculomotor function in ALS, it has been shown that the oculomotor decline follows a sequential pattern: after the initial disruption of executive eye movement control, the pulse-generating part of the brainstem circuity for saccade generation is affected [15].

In the present study, we characterized oculomotor parameters and their association to neuropsychological domains in a cohort of apparently asymptomatic individuals who are carrying mutations in ALS/FTD causing genes and compared C9orf72 carriers to other gene mutation carriers.

### Methods

#### Subjects

Forty-eight participants from families with at least one member diagnosed with ALS according to the revised El Escorial criteria (index patient) were included. Additionally, 54 age- and sex-matched healthy controls with no evidence for family history of ALS or FTD and without any family relations to the gene carriers were included. Statistics of detailed features of all participants are summarized in Table 1. All of the index patient’s family members were contacted and invited to take part in the study. In case of interest, they underwent a series of investigations, including video-oculographic and neuropsychological assessments during the course of 2 days.

All subjects gave written informed consent for the study protocol according to institutional guidelines, which had been approved by the Ethics Committee of Ulm University, Germany (reference no. 68/19).

None of the subjects had a history or clinical manifestations of any neurological disorder, including ALS and/ or FTD. All 48 subjects were tested positive for the most common ALS genes, i.e., 22 carried hexanucleotide repeat expansion mutations in the C9orf72 gene and 17 subjects carried SOD1 mutations; the remaining nine subjects had mutations in rare ALS genes (n = 3 KIF5A; n = 3 FUS/FUS+TBK1; n = 1 NEK1; n = 1 SETX; n = 1 TDP43). The genetic analysis was performed according to a state-of-the-art-protocol [16]. The asymptomatic participants were not informed about their genotypes but had received genetic counselling and knew that they might be at a risk of being a mutation carrier and at risk of developing ALS or FTD later.

### Table 1 Subjects demographic and clinical characterization

|                   | ALS gene carriers | Healthy controls | p     | C9orf72 carriers | SOD1 carriers | p     |
|-------------------|-------------------|------------------|-------|------------------|---------------|-------|
| Gender/male:female| 20:28             | 23:31            | 1a    | 5:17             | 11:6          | 0.12/0.16b|
| Age/years         | 46, (37–52), 19–76| 48, (34–60), 14–77| 0.45c | 47, (39–52), 19–67| 42, (36–55), 22–69| 0.18d |
| ECAS total        | 113, (100–121), 58–129| –               | 0.04c | 114, (111–122), 72–129| 110, (100–121), 58–128| 0.35e |
| ECAS verbal memory| 18, (15–20), 3–22  | –                | 0.28e | 18, (17–19), 6–22  | 17, (15–20), 6–21  | 0.54e |
| ECAS visuospatial function| 12, (12–12), 8–12 | –       | 0.08c | 12, (11–12), 8–12 | 12, (12–12), 11–12 | 0.08c |
| ECAS language     | 27, (23–28), 13–28| –                | 0.28c | 27, (23–28), 17–28| 24, (15–27), 13–28| 0.052c|
| ECAS verbal fluency| 20, (16–22), 10–24| –              | 0.36c | 20, (18–22), 10–24| 19, (16–22), 10–22| 0.36c |
| ECAS executive function| 39, (32–43), 17–46| –        | 0.70c | 40, (35–43), 25–46| 39, (35–42), 17–46| 0.70c |

Data shown as median (interquartile range), minimum–maximum.

aFisher’s exact test refers to comparison between all gene mutation carriers and healthy controls

bFisher’s exact test refers to comparison between C9orf72 carriers and healthy controls and SOD1 carriers and healthy controls

cMann–Whitney U test refers to comparison between all ALS gene carriers and healthy control or between C9orf72 and SOD1 carriers

dKruskal–Wallis analysis of variances on ranks (ANOVA) between healthy controls, C9orf72 carriers and SOD1 carriers
Neuropsychological assessment

For cognitive testing and to exclude clinical evidence of FTD, the German version of the ECAS [17], encompassing ALS-specific (language, verbal fluency and executive functions) and non-ALS-specific tasks (verbal memory, visuospatial abilities), was used with cut-off scores specific to cultural context [18]. The ECAS was performed by all gene carriers and controls. The maximum total score is 136, falling with cognitive decline.

Recording of eye movement

For eye movement recording, the video-oculography device EyeSeeCam® (EyeSeeTec GmbH, Fürstenfeldbruck, Germany) was used. The measurements were acquired in our oculomotor laboratory as previously described [15, 19]. All participants were comfortably seated with their eyes facing a white hemi-cylindrical screen (eyes-to-screen distance of approximately 150 cm) in a softly lit and acoustically shielded environment. To minimize confounding head motion, subjects’ heads were stabilized by an adjustable chin rest.

Smooth pursuit eye movements (SPEM) were tested in horizontal direction by a red laser spot moving sinusoidally at f = 0.375 Hz (range ± 20°, 12 cycles = 32 s). Subjects were instructed to track the target as accurately as possible [19]. Visually guided reactive saccades were pseudo-randomly elicited by lighting red light emission diodes so that each target step proceeded with the previous step (horizontal: 32 target steps, i.e., three times of ± 5, ± 10°, ± 15°, ± 40° and 4 times of ± 20°, targets within range ± 20°, 92.8 s acquisition time) and in a vertical direction (36 target steps, i.e., 4 times of ± 5°, ± 10°, ± 15°, ± 30° and two times ± 20°, targets within range ± 15°, 93.6 s acquisition time). The targets were presented for 2.9 s on average (range 2.1–3.5 s) in a horizontal and for 2.6 s (2.1–3.5 s) in a vertical direction. Subjects were asked to re-fixate on the new target as quickly and accurately as possible and to withhold their gaze shift until the next target appeared [20]. Performance difficulties in fixation may be ascribed to deficits of executive control, typically similar [22, 24]. Oculomotor parameters which correlated with age in healthy controls were adjusted for age using a linear least square fit through the results of the controls [15, 21].

Delayed saccades were tested by pseudo-randomly presenting a new red additive target at 5, 10, 20, and 40° horizontal positions (8 trials to the left and right each) after 1.7 s on average (range 1.1–2.3 s) so that each target step proceeded with the previous step. Subjects were asked to withhold their reaction to the new additive target until an acoustic ‘go’ cue was given. The cue was pseudo-randomly presented acoustically after the new additive target onset [19, 20]. Anti-saccades were tested by pseudo-randomly presenting a green target, twice for both directions, at ± 5, ± 10, ± 15, and ± 20° eccentric horizontal positions after 2.6 s on average (range 2.1–3.0 s). Participants were requested to instantly initiate a gaze shift towards the mirror (opposite) position of the new target. A practice training session of five runs with different eccentricities was administered before the anti-saccade and delayed saccade tasks. Rapid alternating voluntary gaze shifts were evoked in horizontal and vertical directions by requesting subjects to saccade for 30 s as rapidly as possible, back and forth between two steady green targets arranged symmetrically about the primary direction with 20° horizontal or vertical angular separation.

Analysis of eye movement recordings

The interactive MATLAB® (The Mathworks Inc., Natick, MA, USA)-based in-house software package OculoMotor Analysis was used for analysis of eye movement recordings according to a data processing pipeline as previously described in detail [15, 21, 22]. Neither the patient group nor the control group exhibited systematic differences between the right and the left eye so that the binocular recording was merged averaging the monocular recordings [22]. All measurements were visually inspected for quality assurance. Smooth pursuit eye movement yielded the smooth pursuit gain as the ratio of smooth eye velocity to target velocity [15, 19, 22]. Visually guided reactive saccades (VGRS) were characterized by the primary saccade gain, peak eye velocity (each for horizontal, up, down), and the latency (horizontal, vertical) [22, 23]. Saccadic intrusions were examined for horizontal VGRS and computed as the accumulated amplitude of saccades excluding the primary saccades and amplitudes < 2° divided by the considered time interval (i.e., ‘prevalence’ or rate of saccadic intrusions in degrees per second) [21]. For delayed saccades and anti-saccades, the percentage of errors, i.e., saccades before cue and pro-saccades, were obtained as described previously [22]. Rapid alternating voluntary gaze shifts exceeding 10° saccade amplitude were counted for the horizontal and vertical direction. The number of those shifts was arithmetically averaged for both directions since the outcomes were considered to be basically similar [22, 24]. Oculomotor parameters which correlated with age in healthy controls were adjusted for age using a linear least square fit through the results of the controls.

Statistical analysis

The MATLAB®-based Statistics Toolbox was used for statistical data analyses of subject characteristics and eye movement parameters [15, 21]. We cannot assume a normal distribution of the oculomotor parameters so that we used non-parametric interference statistics to compare the eye movement parameters between the cohorts in accordance with previous studies [13, 21]. All statistical tests were 2-sided, and p < 0.05 was considered statistically significant.
Results

Eye movement control was different between the gene mutation carriers (n = 48) compared to healthy controls (n = 54) and between the subgroups C9orf72 (n = 22) and SOD1 carriers (n = 17) compared to healthy controls, respectively (Table 2). Specifically, gene mutation carriers performed in the delayed and anti-saccades tasks with an altered error rate by having difficulties in suppression of unwanted gaze shifts and frequently moving their eyes towards the target (pro-saccade or gaze shift before acoustic cue) (p < 0.01). Many of these errors were immediately corrected, indicating that the subjects had no difficulties in understanding the tasks. The performance of self-initiated gaze shifts revealed no statistical difference between gene carriers and healthy controls. While awaiting a new target position during VGRS, ALS gene carriers showed abnormally large and frequent saccadic intrusions in comparison to controls (p < 0.01). SPEM gain was similar to those of controls. Gain of reactive primary saccades in horizontal and downwards directions revealed no statistical difference, however, the VGRS gain in upward direction was significantly lower in comparison to controls (p < 0.05). Peak eye velocities of reactive primary saccades and latencies were normal.

Subgroup analysis of eye movement control

ANOVA of C9orf72 carriers, SOD1 carriers, and healthy controls indicated significant differences between the three groups for anti- and delayed saccades, the saccadic intrusion rate, and VGRS gain, respectively. Post hoc comparison, shown in Fig. 1, revealed deficits for C9orf72 carriers in those parameters in comparison to controls (anti-saccade error rate, p = 0.0242; delayed saccade error rate, p = 0.0091; saccadic intrusion rate, p = 0.0049). In contrast, the comparison of SOD1 carriers with controls resulted in only one significant finding, i.e., the error rate of delayed saccades (p = 0.0097).

The subjects with C9orf72 mutation showed an altered reactive saccade gain in comparison to controls, both upwards (p = 0.0242) and in horizontal directions (p = 0.0136). In the SOD1 carriers, VGRS gain downwards were normal, likewise the VGRS gains up, down, and in horizontal directions.

Longitudinal comparison of executive eye movement control

Due to the low sample size of follow-up measurements, the carriers of SOD1 and rare gene mutations were excluded from longitudinal data analysis. The comparison of baseline measurements and follow-up measurements in C9orf72 gene carriers demonstrated no significant change in any executive oculomotor domain nor in any cognitive subdomain of the ECAS (verbal fluency, language, executive function, memory, visuospatial function).

Association of executive oculomotor functions with cognitive performance

The total ECAS score of the complete group of ALS gene carriers was associated with the anti-saccade error rate (r = −0.59, p = 0.004) and the number of voluntary gaze shifts (r = 0.46, p = 0.042), i. e., lower ECAS scores corresponded with more frequent errors in the anti-saccade task and a lower number of voluntary inhibited gaze shifts (Table 3). Having a detailed look into particular ECAS domains, those associations were reflected in a correlation of anti-saccade error rate (r = −0.63, p = 0.003) and the number of voluntary gaze shifts (r = 0.55, p = 0.024), respectively, with the executive function performance in ECAS. Although there was no correlation with the total ECAS score, the presence of saccadic intrusions in fixations periods was associated with a worse visuospatial function (r = −0.56, p = 0.014).

For C9orf72 carriers, the error rate of anti-saccades was strongly associated with the performance of the total ECAS (r = −0.74, p = 0.009) and executive function (r = −0.73,
Table 2  Video-oculographic parameters of mutation carriers and healthy controls

|                                | ALS gene carriers | healthy controls | \( p^a \) | \( C9orf72 \) carriers | \( SOD1 \) carriers | ANOVA \( p^b \) |
|--------------------------------|-------------------|-----------------|----------|---------------------|-------------------|----------------|
| Anti-saccades error rate %\(^a\) | 21, (13–41), 0–100 | 15, (6–30), 0–63 | 0.0091  | 24, (12–49), 4–100\(^b\) | 19, (12–36), 0–87 | 0.0254 |
| Delayed saccades error rate %\(^b\) | 12, (5–18), 0–91 | 4, (2–11), 0–21 | 0.0013  | 9, (5–19), 0–91\(^b\) | 14, (6–16), 0–68\(^b\) | 0.0035 |
| Number of voluntary gaze shifts\(^c\) | 55, (42–64), 14–114 | 56, (50–64), 40–98 | 0.116 | 55, (46–61), 21–114 | 51, (42–68), 14–87 | 0.2861 |
| Intrusion rate \( p^d \)/s | 3.7, (2.6–6.3), 1.7–14.9 | 2.9, (2.2–4.5), 1.0–8.7 | 0.0039  | 4.9, (2.8–7.2), 1.7–14.9\(^b\) | 3.1, (2.6–5.6), 2.4–11.7 | 0.0008 |
| SPEM gain % | 90, (76–95), 15–100 | 91, (77–97), 22–111 | 0.8196  | 93, (71–96), 31–100 | 90, (81–95), 15–100 | 0.8316 |
| VGRS (horiz.) gain % | 89, (84–91), 69–95 | 89, (86–93), 69–97 | 0.1871  | 86, (83–90), 69–95\(^b\) | 91, (89–92), 80–94 | 0.0652 |
| VGRS (down) gain % | 93, (89–97), 81–112 | 91, (86–96), 76–110 | 0.1999  | 90, (88–97), 81–104 | 94, (91–97), 81–112 | 0.4842 |
| VGRS (up) gain % | 75, (66–84), 52–92 | 80, (77–84), 62–96 | 0.0220  | 71, (65–83), 52–92\(^b\) | 76, (72–85), 57–92 | 0.0070 |
| VGRS (horiz.) velocity \( p^e \)/s | 349–574 | 245–536 | 0.6556  | 440, (398–474), 524–572 | 415, (394–455), 572–524 | 0.8144 |
| VGRS (down) velocity \( p^f \)/s | 391, (329–444), 254–579 | 393, (349–437), 227–538 | 0.4159  | 363, (310–454), 254–579 | 391, (332–421), 276–462 | 0.5936 |
| VGRS (up) velocity \( p^g \)/s | 434, (376–474), 309–551 | 432, (405–487), 216–599 | 0.5730  | 445, (393–502), 309–550 | 422, (369–462), 310–529 | 0.5611 |
| VGRS (horiz.) latency \( p^h \)/ms | 219, (208–236), 178–304 | 216, (202–236), 183–413 | 0.7048  | 216, (203–235), 178–304 | 225, (207–239), 190–255 | 0.9268 |
| VGRS (vert.) latency \( p^i \)/ms | 230, (213–252), 189–355 | 237, (215–253), 193–371 | 0.8748  | 231, (211–252), 189–307 | 226, (220–252), 193–287 | 0.8816 |

Data are presented as median (interquartile range), minimum–maximum. Bold values indicate significance at \( p < 0.05 \). Post hoc statistical comparisons for \( C9orf72 \) carriers vs. healthy controls and \( SOD1 \) carriers vs. healthy controls which reached statistical significance are indicated as \( \# \)

\( ^a \) Mann–Whitney \( U \) test between healthy controls and ALS gene carriers

\( ^b \) Kruskal–Wallis analysis of variances of ranks (ANOVA) between healthy controls, subjects with \( C9orf72 \) mutation and \( SOD1 \) mutation

\( ^c \) Errorious responses (pro-saccades)

\( ^d \) Errorious responses (saccades before cue)

\( ^e \) Saccades >\( 10^\circ \) counted within 30 s

\( ^f \) Saccadic intrusions >\( 2^\circ \) excluding the primary saccade, computed as the sum of saccades within VGRS acquisition time

\( ^g \) Gain of VGRS aimed at targets of \( 20^\circ \) eccentricity obtained by linear fitting saccade amplitudes as a function of target steps

\( ^h \) Peak eye velocity of VGRS aimed at targets of \( 20^\circ \) eccentricity obtained by non-linear interpolation along the main sequence

\( ^i \) Latencies of VGRS with respect to primary saccade onset

\( p = 0.034 \) similar to all ALS gene carriers’ ECAS executive function. In addition, a strong correlation between ECAS verbal memory score and anti-saccade error rate (\( r = −0.73, \ p = 0.0358 \)) was shown. Other significant correlations between executive eye movement parameters and any ECAS section were not observed. In the subgroup of \( SOD1 \) carriers, only the performance of self-initiated gaze shifts correlated with the ECAS executive function score (\( r = −0.82, \ p = 0.040 \)), while the error rate of anti-saccades did not.

**Discussion**

The video-oculographic data provided evidence for alterations in executive eye movement parameters in presymptomatic carriers of gene mutations for ALS. More specifically, impairment in executive oculomotor control was primarily observed in \( C9orf72 \) repeat expansion carriers, long before any overt clinical signs of ALS or FTD pathologies known to be associated with \( C9orf72 \) mutations. Compared to other ALS gene mutations, the repeat expansion in the \( C9orf72 \) gene is common in both familial ALS and FTD [1]. At the time of study inclusion, it is not to be predicted whether \( C9orf72 \) mutations carriers will develop either pathology of ALS or FTD in the future. With regard to oculomotor pathology, both pathologies seem to share common preclinical manifestations in those subjects with \( C9orf72 \) repeat expansions: \( C9orf72 \) carriers had a higher saccadic intrusion rate and they performed significantly worse in suppressing unwanted gaze shifts toward a new target during anti-saccade and delayed saccade tasks, all signs of impaired executive control of eye movements. These results are in line with the reported executive dysfunction in cognitive...
tasks at behavioral level reported for ALS patients [17, 25, 26]. Executive dysfunction is also characteristic for fronto-temporal dementia which shares neuropathological, clinical, radiological, and genetic overlap with ALS [27]. ECAS, as an ALS-specific test that can be performed even in the presence of motor impairments, focuses on the assessment of executive functions. Thus, it was possible to detect correlations to the executive abilities in the oculomotor tasks.

We thus present hereby further evidence for clinical overlap in C9orf72 mutation carriers who share executive functions also at the oculomotor level. Note that neither C9orf72 nor SOD1 carriers faced challenges in initiating saccades, which would rather be a sign of disturbed pontocerebellar circuits or impaired oculomotor brainstem nuclei. It should be noted that SOD1 carriers also performed significantly worse than controls with respect to error rate in the delayed saccades task, but these data were not correlated with their ECAS performance. Taken together, the investigations of primarily executive oculomotor functions further support the notion of a prefrontal dysfunction in subjects with C9orf72 mutation [7]. The different characteristics of C9orf72 vs. SOD1 gene carriers are also supported by associations between executive oculomotor parameters and cognitive performance. The performance in the anti-saccade error task significantly correlated with the cognitive performance in the ECAS in C9orf72 gene carriers but not in SOD1 gene carriers. Although it has not been entirely specified yet which cognitive functions are involved in the correct execution of anti-saccades, attention plays a role, as it does for verbal memory and executive functions. Most importantly, these alterations in executive functions remained unchanged over time in C9orf72 carriers, implying rather a feature of executive dysfunction which is not a matter of cognitive decline over time but rather a general trait in itself [28].

Impaired cognitive function may be linked to early central nervous system development [29]. Recently, it was shown that presymptomatic C9orf72 carriers showed cerebro-structural and cognitive dysfunctions unrelated to time [7]. The longitudinal assessments in a subset of subjects showed no significant differences in any executive oculomotor domain so that no change over the given time could be observed. None of the ALS gene carriers was diagnosed with autism or showed any clinical sign of autism; however, according to previous data [7], developmental tardiness might be a general trait in C9orf72 carriers. It can be speculated that the alterations in the executive oculomotor parameters in C9orf72 carriers, especially the anti-saccade error rate, might be indicating developmental deficits originating in early childhood. This hypothesis arises from the fact that these oculomotor functions develop in the first years of life: young children face challenges in suppressing unwanted prosaccades in the anti-saccade task [30, 31], and only about...
Table 3  Correlation coefficients $r$ of executive oculomotor parameters with neuropsychological ECAS scores (total and single sections) in presymptomatic ALS gene carriers

| ALS gene carriers | Anti-saccades error rate/% | Delayed saccades error rate/% | Number of voluntary gaze shifts | Intrusion rate°/s | C9orf72 carriers | Anti-saccades error rate/% | Delayed saccades error rate/% | Number of voluntary gaze shifts | Intrusion rate°/s | SOD1 carriers | Anti-saccades error rate/% | Delayed saccades error rate/% | Number of voluntary gaze shifts | Intrusion rate°/s |
|-------------------|---------------------------|--------------------------------|---------------------------------|-------------------|-----------------|---------------------------|--------------------------------|---------------------------------|-------------------|-----------------|---------------------------|--------------------------------|--------------------------------|-------------------|
| ECAS total        | -0.59                     | -0.32                          | 0.46                            | -0.33             | -0.74           | -0.53                     | 0.28                            | -0.56                           | -0.68             | -0.13          | 0.59                       | -0.14                           | -0.14                           | 0.33                            |
| ECAS verbal memory| -0.42                     | -0.14                          | 0.29                            | -0.11             | -0.73           | -0.38                     | 0.10                            | -0.23                           | -0.50             | -0.02          | 0.33                       | 0.05                            | -0.05                           | 0.05                            |
| ECAS visuospatial function | -0.36                   | -0.34                          | 0.19                            | -0.56             | -0.35           | -0.39                     | 0.17                            | -0.63                           | -                  | 0.20           | 0.19                       | -0.20                           | -0.20                           | -0.56                           |
| ECAS language     | -0.29                     | -0.18                          | 0.24                            | -0.15             | -0.54           | -0.40                     | 0.21                            | -0.54                           | -0.42             | -0.12          | 0.33                       | 0.05                            | -0.05                           | 0.05                            |
| ECAS verbal fluency | -0.43                  | -0.22                          | 0.35                            | -0.28             | -0.42           | -0.20                     | 0.33                            | -0.41                           | -0.68             | -0.30          | 0.45                       | -0.19                           | -0.19                           | -0.30                            |
| ECAS executive function | -0.63                 | -0.37                          | **0.55**                        | -0.42             | -0.73           | -0.67                     | 0.30                            | -0.62                           | -0.77             | -0.07          | **0.82**                   | -0.30                           | -0.30                           | -0.30                            |

The matrix represents the correlation of anti-saccade error rate, the error rate of delayed saccades, number of voluntary gaze shifts, and the saccadic intrusion rate with the total ECAS score and the following ECAS sections: verbal memory, visuospatial function, language, verbal fluency, and executive function. Significance: unbold, $p > 0.05$; italics, $p < 0.05$; bold, $p < 0.01$
the age of 10 there is an improvement in the ability to suppress reflexive saccades in the sense of a strong decrease of the amount of anti-saccade errors. Thus, we hereby support the assumption that C9orf72 mutations are associated with impairments in oculomotor tasks which may indicate delayed brain development. It may thus represent a tardiness in neurological development in C9orf72 mutations as has been shown in synaptic regulation, excitotoxicity [32], neural development [9], and cognition at the behavioral level [28]. These changes were unrelated to time and can rather be regarded as a general trait in C9orf72 carriers. As this pattern was not observed in SOD1 mutation carriers, it can be regarded as specific to C9orf72 alterations, as has been previously been implied by neuroanatomical and cellular pathway involvement [9, 29]. In addition to alterations in executive oculomotor functions, C9orf72 carriers showed hypometric horizontal and asymmetric vertical saccades which indicate ‘genuine’ oculomotor dysfunctions, although the change of the horizontal saccade gain is commonly observed in patients with FTD [33] but not in ALS patients [12, 15] and might be regarded as another element of the C9orf72-associated overlap of motor neuron disease and frontotemporal pathology.

This study has a number of limitations. Due to the limited sample size of rare gene mutations, we could not include them in subgroup comparison. A limitation of the longitudinal analysis is the low number of participants, especially for follow-up. For the future, a validation of these results with a larger group would be favourable. Also, mutation carriers were only screened for cognitive performance and future work might include more intensive neuropsychological testing, in addition with more longitudinal assessments. Nevertheless, the association of executive function at the oculomotor level which was closely associated with the cognitive behavioral level very well implies a disruption of frontal involvement in C9orf72 mutation carriers, long before any overt clinical signs of disease onset of either ALS or FTD.

So overall, we hereby present evidence for oculomotor impairments associated with C9orf72 repeat expansions in apparently presymptomatic stages, which further support the concept of developmental delay associated with these mutations, especially in prefrontal areas. Biomarkers will play an important role in future therapeutic decisions now that C9orf72 mutation carriers can be identified by genetic testing many decades before symptoms begin [34], given that, with the emergence of antisense oligonucleotide therapies, the characterization of presymptomatic disease burden has now gained practical relevance [35]. Like in presymptomatic Huntington’s disease [36] and pre-ataxic Machado–Joseph disease [37] individuals, the recording of eye movements in presymptomatic C9orf72 gene carriers may have the potential as a biological marker. Thus, video-oculographic recording as an unbiased assessment of the neuropsychological condition might further prove its potential as a technical biomarker in the longitudinal work-up of the clinical condition from the presymptomatic to the symptomatic stage. According to our findings, C9orf72 carriers will play a special role in this biomarker work-up as their oculomotor and cognitive impairments probably develop early in life already.

Acknowledgments The authors would like to thank Ralph Kühne and Dr. Martin Gorges for help with the eye movement recordings.

Author contributions AB: analysis or interpretation of the data, drafting or revising the manuscript for intellectual content. AK: design or conceptualization of the study. JF: analysis or interpretation of the data, drafting or revising the manuscript for intellectual content. MSK: drafting or revising the manuscript for intellectual content. CL: drafting or revising the manuscript for intellectual content. H-PM: drafting or revising the manuscript for intellectual content. EHP: drafting or revising the manuscript for intellectual content. ACL: drafting or revising the manuscript for intellectual content. DL: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript for intellectual content. JK: design or conceptualization of the study, analysis or interpretation of the data, drafting or revising the manuscript for intellectual content.

Funding Open Access funding enabled and organized by Projekt DEAL.

Availability of data and material Data are available upon reasonable request and require a formal data sharing agreement, which must include details on how the data will be stored, who will have access to the data and intended use of the data, and agreements as to the allocation of intellectual property.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethics approval Study was approved by the Ethics Committee of Ulm University, Germany (reference no. 16/19).

Consent to participate All subjects gave written informed consent.

Consent for publication All subjects gave written informed consent.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Benatar M, Wuu J, Andersen PM et al (2018) Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion: neurofilament light in presymptomatic ALS. Ann Neurol 84:130–139. https://doi.org/10.1002/ana.25276

2. Chipika RH, Siah WF, McKenna MC et al (2020) The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface? J Neurol. https://doi.org/10.1007/s00415-020-10289-5

3. van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390:2084–2098. https://doi.org/10.1016/S0140-6736(17)31287-4

4. Beeldman E, Raaphorst J, Klein Twennaar M et al (2016) The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry 87:611–619. https://doi.org/10.1136/jnnp-2015-310734

5. Lulé D, Böhm S, Müller H-P et al (2018) Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosis. Cortex 101:163–171. https://doi.org/10.1016/j.cortex.2018.01.004

6. Kasper E, Schuster C, Machts J et al (2014) Microstructural white matter changes underlying cognitive and behavioural impairment in ALS—an in vivo study using DTI. PLoS ONE 9:e114543. https://doi.org/10.1371/journal.pone.0114543

7. Lulé DE, Müller H-P, Finsel J et al (2020) Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriers—a developmental disorder. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-323671

8. DeJesus-Hernandez M, Mackenzie IR, Boeve BF et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-Linked FTD and ALS. Neuron 72:245–256. https://doi.org/10.1016/j.neuron.2011.09.011

9. Yeh T-H, Liu H-F, Li Y-W et al (2018) C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Exp Neurol 304:114–124. https://doi.org/10.1016/j.expneurol.2018.03.002

10. Benatar M, Wuu J (2012) Presymptomatic studies in ALS: rationales, challenges, and approach. Neurology 79:1732–1739. https://doi.org/10.1212/WNL.0b013e318269b1d

11. Proudfoot M, Menke RAL, Sharma R et al (2015) Eye-tracking in presymptomatic amyotrophic lateral sclerosis. J Neurol 262:1037–1046. https://doi.org/10.1007/s00415-014-7538-3

12. Shaunak S, Orrell RW, O’Sullivan E et al (1995) Oculomotor function in amyotrophic lateral sclerosis: evidence for frontal impairment. Ann Neurol 38:38–44. https://doi.org/10.1002/ana.410380109

13. Donaghy C, Pinnock R, Abrahams S et al (2010) Slow saccades in bulb-onset motor neuron disease. J Neurol 257:1134–1140. https://doi.org/10.1007/s00415-010-5478-7

14. Boxer AL (2012) Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Arch Neurol 69:509. https://doi.org/10.1001/archneurol.2011.1021

15. Gorges M, Müller H-P, Lulé D et al (2015) Eye movement deficits are consistent with a staging model of pTED-43 pathology in amyotrophic lateral sclerosis. PLoS ONE 10:e0142546. https://doi.org/10.1371/journal.pone.0142546

16. Zondler L, Müller K, Khalaj S et al (2016) Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol 132:391–411. https://doi.org/10.1007/s00401-016-1548-y

17. Lulé D, Burkhardt C, Abdulla S et al (2015) The edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen: a cross-sectional comparison of established screening tools in a German-Swiss population. Amyotroph Lateral Scler Frontotemporal Degener 16:16–23. https://doi.org/10.3109/21678421.2014.959451
35. Bede P, Siah WF, McKenna MC, Li Hi Shing S (2020) Consideration of C9orf72-associated ALS-FTD as a neurodevelopmental disorder: insights from neuroimaging. J Neurol Neurosurg Psychiatry 91:1138–1138. https://doi.org/10.1136/jnnp-2020-324416

36. Júlio F, Caetano G, Januário C, Castelo-Branco M (2019) The effect of impulsivity and inhibitory control deficits in the saccadic behavior of premanifest Huntington’s disease individuals. Orphanet J Rare Dis 14:246. https://doi.org/10.1186/s13023-019-1218-y

37. Oliveira CM, Leotti VB, Bolzan G et al (2021) Pre-ataxic changes of clinical scales and eye movement in machado-joseph disease: BIGPRO study. Mov DISORD Epub mds. https://doi.org/10.1002/mds.28466